Sublingual Tablet Immunotherapy Improves Quality of Life in Adults With Allergic Rhinoconjunctivitis
Year: 2024
Type: article
Abstract: BACKGROUND: Allergic rhinitis with or without conjunctivitis can negatively impact many aspects of quality of life (QoL). The efficacy and safety of standardized quality (SQ) sublingual immunotherapy (SLIT) tablets have been confirmed across large clinical trials in adults with grass, tree, ragweed, and house dust mite (HDM) allergic rhinitis with or without conjunctivitis. OBJECTIVE: This pooled analysis investigates whether the reduction in symptom burden found across the clinical trials is supported by improvements in QoL. METHODS: A total of 11 phase II/III randomized placebo-controlled trials across the SQ grass, tree, ragweed, and HDM SLIT tablets (grass: N = 3179; ragweed: N = 767; tree: N = 634; HDM: N = 2221) were included. QoL was assessed using the standardized Rhinitis Quality of Life Questionnaire (RQLQ), with the exception of 3 grass trials, which used the nonstandardized version. The overall RQLQ scores were expressed as a mean of 7 domains. In the pooled analysis, treatment was used as fixed effect; and the trial, and the interaction between region/country and trial as random effects. RESULTS: The pooled analysis showed consistent and statistically significant improvements in overall RQLQ scores across all 4 SQ SLIT tablets versus placebo (pooled estimate [95% CI], P value-grass: -0.20 [-0.28 to -0.12], P < .001; tree: -0.42 [-0.58 to -0.26], P < .001; ragweed: -0.36 [-0.55 to -0.17], P < .001; HDM: -0.28 [-0.39 to -0.17], P < .001). Furthermore, significant improvements versus placebo for all 4 SQ SLIT tablets were seen across the 7 individual domains. CONCLUSIONS: The proven efficacy of SQ SLIT tablets to reduce symptoms across 4 of the most common respiratory allergens is supported by concurrent significant improvements in RQLQ scores overall and for all 7 domains.
Authors: Michael S. Blaiss, Stephen R. Durham, David Bernstein, Thomas Stranzl, Morten Lindholm, Hendrik Nolte, Kristian Funding Andersen, Graham Roberts
Institutions: Augusta University, Royal Brompton Hospital, Imperial College London, Bernstein Clinical Research Center, University of Cincinnati, ALK-Abelló (Denmark), ALK-Abelló (Spain), University Hospital Southampton NHS Foundation Trust, NIHR Southampton Biomedical Research Centre, St Mary's Hospital, David Hide Asthma and Allergy Research Centre, University of Southampton
Language: English
Subfield: Immunology and Allergy
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,000
Funders: Abbott Laboratories, Amgen, AstraZeneca, GlaxoSmithKline, Sanofi, Teva Pharmaceutical Industries, Regeneron Pharmaceuticals, Immune Tolerance Network, BioCryst, Aimmune Therapeutics, National Institute for Health and Care Research, Seqirus, National Institutes of Health, Genentech, Allergopharma, Medical Research Council, National Institute of Allergy and Infectious Diseases
OpenAlex ID: W4391482263